|
Abatacept Clinical Trials
6 actively recruiting trials across 5 locations
Also known as: Orencia
Pipeline
Early 1: 1Phase 1: 1Phase 2: 1Phase 3: 2Phase 2/3: 1
Top Sponsors
- Duke University2
- University of Nebraska1
- National Cancer Institute (NCI)1
- Leland Metheny1
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology1
Indications
- Cancer4
- Arthritis2
- Polyarticular Course Juvenile Idiopathic Arthritis (JIA)1
- Myelodysplastic Syndrome Other1
- Acute Lymphatic Leukemia1
Other1 trial
San Francisco, California1 trial
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
University of California San Francisco Pediatric Rheumatology
Phase 3
Bethesda, Maryland1 trial
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Institutes of Health Clinical Center
Phase 1
Omaha, Nebraska1 trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
University of Nebraska Medical Center
Phase 3
Durham, North Carolina1 trial
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Duke University Health System
Early 1
Cleveland, Ohio1 trial
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.